CONTEXT: Safe and effective strategies to curb rising obesity prevalence rates are urgently needed and medications may play a more prominent role in future therapeutic regimens. OBJECTIVE: To review systematically the long-term efficacy and safety of approved antiobesity medications. DATA SOURCES: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Current Science Meta-register of Controlled Trials, and reference lists of original studies and reviews were searched. Drug manufacturers and two obesity experts were contacted. No language restrictions were imposed. STUDY SELECTION: Double-blind, randomized controlled studies of approved antiobesity medications with follow-up periods of 1 y or greater were eligible for inclusion. DATA EXTRACTION: Two reviewers independently assessed all potentially relevant studies for inclusion and methodological quality using standardized abstraction forms. RESULTS: A total of 11orlistat (n ¼ 6021) and three sibutramine (n ¼ 929) studies met inclusion criteria. Attrition rates averaged 33% in orlistat studies and 48% in sibutramine studies. A random effects model was used for meta-analysis. Compared to placebo, orlistat-treated patients displayed a 2.7 kg (95% CI: 2.3-3.1 kg) or 2.9% (95% CI: 2.3-3.4%) greater reduction in weight and patients on sibutramine displayed a 4.3 kg (95% CI: 3.6-4.9 kg) or 4.6% (95% CI: 3.8-5.4%) greater weight reduction after 1 y of follow-up. The number of patients achieving 10% or greater weight loss was 12% (95% CI: 8-16%) higher with orlistat and 15% (95% CI: 4-27%) higher with sibutramine compared to placebo. Orlistat caused gastrointestinal side effects and sibutramine increased blood pressure and pulse rate. CONCLUSION: There is a relative paucity of long-term studies of antiobesity agents. In weight loss trials of 1-y duration, orlistat and sibutramine appear modestly effective in promoting weight loss. Longer, more methodologically rigourous studies that are powered to examine end points such as mortality and cardiovascular morbidity are required.
Introduction
In the past several decades, worldwide prevalence rates of obesity and overweight have risen to epidemic proportions. The prevalence of obesity in adults has now reached 31% in the United States (US) and over 25% in many other industrialized nations.
1,2 A total of 65% of adults and 16%
of adolescents in the US are now overweight. 2, 3 Certain ethnic populations, such as African and Mexican Americans, appear to be at particularly high risk. 2, 4 The economic burden of obesity-related illness in many countries is substantial, with estimates ranging from 2 to 7% of total health-care expenditures and billions of dollars in direct and indirect costs to society. 5, 6 Obesity and overweight are associated with increases in overall mortality as well as a number of chronic conditions, including cardiovascular disease, cancer, and osteoarthritis. [7] [8] [9] [10] [11] Weight loss of as little as 5-10% of initial body weight is associated with an improvement in cardiovascular risk factors, and cohort studies have demonstrated that voluntary weight loss in overweight or obese subjects is associated with a reduction in mortality rates. [12] [13] [14] [15] [16] [17] Nonpharmacological methods of obesity therapy have demonstrated short-term efficacy. Unfortunately, one-third to two-thirds of the weight lost is regained within 1 y and almost all is regained within 5 y. 18, 19 Obesity guidelines currently recommend that drug therapy be considered in conjunction with nonpharmacological therapy for patients with a body mass index (BMI) greater than or equal to 30 kg/ m 2 or a BMI of 27-30 kg/m 2 with one or more obesity-related disorders. 20 Approved antiobesity medications can be separated into two broad categories: (1) inhibitors of intestinal fat absorption: orlistat, a drug that inhibits pancreatic and other lipases, is the only agent currently available in this class; and (2) medications that act to suppress appetite, increase satiety, or increase thermogenesis, primarily by modifying central nervous system neurotransmission: this category includes all other antiobesity drugs. Sibutramine, which inhibits reuptake of serotonin and norepinephrine, is the most recently approved agent. The majority of randomized controlled trials (RCTs) evaluating antiobesity medications have been of short duration and have not assessed the impact of these drugs on cardiovascular, cancer-related or total mortality. Previous reviews that have included studies up to December 2000 suggest that the magnitude of weight loss induced by such agents is approximately 5 kg or less. [21] [22] [23] However, shortterm efficacy is a suboptimal end point, especially if recidivism is common when therapy is stopped. The longterm safety of antiobesity medications is also a concern given previous evidence linking fenfluramine and dexfenfluramine to valvular heart disease and pulmonary hypertension, and recent concerns regarding sibutramine and increased cardiovascular risk. [24] [25] [26] [27] [28] Given the rising prevalence of obesity and the potential for more widespread use of antiobesity drugs, we sought to review the available evidence regarding the long-term efficacy and safety of such agents.
Objective
The purpose of this review was to determine the efficacy and safety of antiobesity drug therapy in clinical trials of at least 1-y duration. This publication concentrates on weight loss studies and represents a condensed version of a larger review published within the Cochrane Collaboration, which also contains information on weight maintenance trials. 29 
Methods

Search strategy
The following sources were searched: the Cochrane Controlled Trials Register (Cochrane Library Third Quarter, 2002), MEDLINE (1966 MEDLINE ( -2002 , December week 3), EMBASE (1980-2002, week 51) , and the metaRegister of Controlled Trials (www.controlled-trials.com). Reference lists of original studies, narrative reviews, and previous systematic reviews were also examined. Drug manufacturers and two experts in the field of obesity were contacted in an effort to identify unpublished studies.
Criteria for inclusion of studies
Only double-blind, RCTs of antiobesity agents were considered for inclusion. Quasirandomized, open-label, and crossover trials were excluded. Included studies had to (1) enroll patients with BMI levels of Z30 or Z27 kg/m 2 plus one or more obesity related comorbidities, (2) include a placebo control group or directly compare two or more antiobesity drugs, and (3) have a minimum follow-up period of 1 y from the point of randomization. Studies published in abstract form only were not included because of the difficulty in judging study quality from an abstract alone.
No language or publication restrictions were applied. Studies evaluating the following medications were included: sibutramine, phentermine, mazindol, diethylpropion, benzphetamine, phendimetrazine, benzocaine, and orlistat. Drugs withdrawn from the market due to unacceptable side-effect profiles (fenfluramine, dexfenfluramine, phenylpropanolamine) were not included.
Outcomes
The primary outcome was weight loss, expressed as percentage of baseline weight lost and number of kilograms lost. Weight loss was also expressed as the proportion of patients achieving at least 5 and 10% weight loss. Secondary outcomes included total mortality, cardiovascular morbidity/mortality, change in blood pressure, lipid parameters, BMI, waist circumference, and glycemic control.
Subgroup analyses were performed after stratifying by baseline cardiovascular risk and the presence or absence of diabetes. Studies were considered 'high cardiovascular risk' if they limited enrolment to patients with hypertension, impaired glucose tolerance, diabetes, or dyslipidemia. The remainder of the trials were classified as 'low cardiovascular risk'.
Trial selection and data extraction One reviewer (RP) performed the electronic searches and reviewed the results. Two reviewers (RP and SL) independently assessed all potentially relevant studies for inclusion and methodological quality. Disagreements were resolved by consensus. Reviewers were not blinded to the journal, author, or institution of publication. Two reviewers (RP and SL) extracted and recorded data using double data entry.
Quality assessment of studies The Verhagen Delphi list for quality assessment of RCTs was used as a guide to assess study quality (Table 1) . 30 A valid
Long-term pharmacotherapy for overweight and obesity R Padwal et al intention-to-treat (ITT) analysis was considered present if studies analyzed patients in the groups to which they were randomized and the attrition rate was acceptable. 31 Attrition rates were deemed to be acceptable if the results of the study were not materially affected, given the observed drop-out rate. Methodological quality was reported in a descriptive fashion, rather than using a numeric quality score, as such scores can be inaccurate and poorly reproducible when used to differentiate between high-and low-quality studies.
32
Cohen's k coefficient was calculated to assess inter-rater agreement for trial selection and methodological quality.
Data analysis
Statistical analysis included the calculation of risk difference for dichotomous outcomes and weighted mean difference for continuous outcomes. Quantitative analyses of outcomes were based on ITT results. A weighted treatment effect was calculated using the RevMan 4.2 package and a random effects model was used for meta-analysis. A w 2 test for heterogeneity was performed for each outcome and all outcomes were also analyzed using a fixed effects model to determine if results were robust.
Search results
Search results are summarized in the Quality of Reporting of Meta-analyses (QUOROM) flow diagram ( Figure 1 ). 33 In all, 232 potentially relevant RCTs were identified and screened for retrieval. We did not find any head-to-head or combination therapy studies that lasted at least 1 y and met inclusion criteria. We also were unable to locate any unpublished studies. If a study contained both weight loss and weight maintenance phases, only data from the weight loss phase is included in this review. Results for weight maintenance interventions and data on excluded studies can be found in the full Cochrane Review. 29 Cohen's k coefficient for inter-rater agreement measured 0.94 for trial selection and 0.85 for study quality.
Description of included studies
All studies Only studies evaluating orlistat or sibutramine met our inclusion criteria. A total of 11 orlistat and three sibutramine weight loss studies were included in the final review ( Table 2 ). All had follow-up periods of 1 y.
Orlistat Population and setting. The 11 identified trials included 6021 participants with an average BMI of 35.7 kg/m 2 , weight of 100 kg, and age of 49 y (Table 2) . [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Study size ranged from 218 to 892 participants, 72% of whom were female participants and 79% Caucasian. Six studies specifically enrolled higher risk populations: three recruited patients with type II diabetes and three enrolled obese patients with at least one additional cardiovascular risk factor (hypertension, dyslipidemia, type II diabetes, or impaired glucose tolerance). 36, [40] [41] [42] [43] [44] Interventions. The dose of orlistat used in all trials was 120 mg t.i.d., which is the standard dose recommended for use in clinical practice. Two studies also included 60 mg t.i.d. study arms, showing efficacy and tolerability that was intermediate between that of placebo and 120 mg t.i.d. study ?
Studies with a question mark provided baseline data at the start of the run-in period and not at the point of randomization.
b Although not explicitly stated in any study, we assumed that the term 'double-blinding' referred to blinding of patients and care providers. (1) analyze patients in the groups to which they were originally randomized and (2) demonstrate an acceptable attrition rate.
Long-term pharmacotherapy for overweight and obesity R Padwal et al arms. 35, 39 The remainder of this review will focus on results obtained using 120 mg t.i.d. dosage regimen. All patients were instructed to follow a standardized, lowfat (less than 30% of caloric intake) hypocaloric diet. Other co-interventions varied across studies and included dietary counselling, exercise counselling, food intake diaries, and educational literature or videos. Specific co-interventions for each study are summarized in Table 2 .
Sibutramine Population and setting. The three sibutramine studies included 929 participants with an average BMI of 33.4 kg/ m 2 , weight of 96 kg, and age of 47 y (Table 2) . [45] [46] [47] Study size ranged from 220 to 485 participants; 80% were female participants and 75% were Caucasian. Two trials limited enrollment to obese, hypertensive patients. 46, 47 Interventions. Two trials began with a starting dose of sibutramine 5 mg daily, which was increased to 20 mg daily by week 8. 46, 47 The remaining trial randomized to placebo, and 10 and 15 mg arms. 45 For the remainder of this review, results from this trial refer to the 15 mg arm. Dietary advice was similar to that used in orlistat studies.
Methodological quality of included studies
The methodological quality of included studies is summarized in Table 1 . Only two orlistat and one sibutramine trial adequately described methods of randomization and allocation concealment. 34, 38, 45 The remaining studies merely stated that randomization was performed without giving further details. None of the studies met the definition of true ITT analysis because all trials were hampered by high attrition rates, which averaged 33% for orlistat studies and 43% for sibutramine trials. In all, 11 studies had attrition rates that were higher than 20% in each study arm. 35, [37] [38] [39] [41] [42] [43] [44] [45] [46] [47] The most common reasons for premature withdrawal were treatment refusal, loss to follow-up, and adverse effects. Authors attempted to address this limitation by using a lastobservation-carried-forward ITT analysis, in which the last observation on record was used as a surrogate for the final value. Patients with only a baseline weight recording and no follow-up measurements were excluded from further analysis (less than 5% of participants per study).
Outcomes
Orlistat Weight loss. All 11 studies reported greater reductions in weight in the orlistat group compared to placebo (Table 3 and Figure 2 ). When results were pooled, weight loss was 2.7 kg (95% CI: 2.3-3.1 kg; 11 studies) or 2.9% (95% CI: 2.3-3.4%; 10 studies) greater in orlistat-treated patients. Compared to placebo therapy, 21% (95% CI: 19-24%; 11 studies) more patients in the orlistat group achieved at least 5% weight loss and 12% (95% CI: 8-16%; 10 studies) more achieved at least 10% weight loss. Subgroup analysis showed that orlistat was slightly less effective in trials that enrolled higher risk populations and in patients with diabetes (Table 3) .
Secondary outcomes.
No mortality or cardiovascular morbidity data were found. Orlistat therapy reduced cholesterol and blood pressure levels and improved glycemic control compared to placebo (Table 4) .
Adverse effects. Gastrointestinal events were the predominant side effect associated with orlistat therapy. Fatty/oily stool, fecal urgency, and oily spotting occurred at frequency rates of 15-30% in most studies. A total of 7% of orlistattreated patients reported fecal incontinence compared to 1% of those taking placebo. 34, 35, 39 Levels of fat-soluble vitamins (A, D, E) and beta-carotene were reportedly lowered by orlistat therapy, with vitamin D the most frequently affected. 34, 36, 38, 39 However, no study reported clinical vitamin deficiency as an end point.
Sibutramine
Weight loss. On pooling results from all three trials, patients on sibutramine therapy lost 4.3 kg (95% CI: 3.6-4.9 kg) or Long-term pharmacotherapy for overweight and obesity R Padwal et al 4.6% (95% CI: 3.8-5.4%) more weight than those taking placebo (Table 3 and Figure 3 ). In all, 34% (95% CI: 28-40%) more patients achieved at least 5% weight loss and 15% (95% CI: 4-27%) more achieved at least 10% weight loss in the sibutramine arm compared to placebo. Statistical heterogeneity was observed in the latter outcome (P ¼ 0.0008), Diet was as follows: 600 kcal/day deficit (1200 kcal/day minimum) for first 6 months, then 900 kcal/day deficit (1000 kcal/day minimum). A typical diet derived 30% of calories from fat, 50% from carbohydrates, and 20% from protein, with maximum cholesterol content of 300 mg/day. b 600 kcal deficit diet adjusted to 800 kcal deficit at 6 months. Minimum diet of 1200 kcal/day.
Long-term pharmacotherapy for overweight and obesity R Padwal et al possibly due to differences in the magnitude of treatment effect observed between predominantly hypertensive and nonhypertensive populations. 29 Secondary outcomes. Secondary outcomes for sibutramine are summarized in Table 4 . Lack of measures of variability and substantial statistical heterogeneity limited quantitative meta-analysis for several outcomes. As with orlistat studies, no mortality or cardiovascular morbidity data were found. Sibutramine had no clinically or statistically significant effect on total cholesterol, LDL cholesterol, and glycemic control.
Adverse effects
Blood pressure and pulse rate. Sibutramine therapy was associated with net increases in both systolic blood pressure of 0.8 mmHg (95% CI: 0.6-1.1 mmHg) and diastolic blood pressure of 0.7-3.3 mmHg (Po 0.05 for all three studies) compared to placebo (Table 4) . Data were not quantitatively combined for diastolic blood pressure due to substantial statistical heterogeneity. Sibutramine treatment was also associated with pulse rate increases of 4-6 beats per minute, which was statistically significant (Po0.05) in two trials. 46, 47 Other adverse effects. Insomnia, nausea, dry mouth, and constipation were more common in patients on sibutramine therapy, occurring at frequency rates of 7-20%.
Discussion
In summary, studies evaluating the long-term efficacy of antiobesity pharmacotherapy are limited to orlistat and sibutramine. In placebo-controlled weight loss trials of 1-y duration, treatment with orlistat reduced weight by 2.7 kg or 2.9%. Orlistat-treated patients displayed improvements in total cholesterol, LDL cholesterol, blood pressure, and glycemic control, but had increased rates of gastrointestinal side effects and slightly lower HDL levels. Sibutramine Figure 2 Orlistat weight loss (kg). Long-term pharmacotherapy for overweight and obesity R Padwal et al therapy produced 4.3 kg (4.6%) greater reductions in weight compared to placebo in weight loss trials of 1-y duration. Small improvements in HDL cholesterol and triglyceride levels were seen, but sibutramine therapy was associated with a net increase in blood pressure. These results confirm findings reported in earlier reviews of orlistat and sibutramine. 22, 23 A minority of patients (12-15%) do achieve 10% or greater weight loss, although it is difficult to predict which patients will respond to this extent without a therapeutic trial. Responders may be identified after a few months of therapy because near-maximal weight loss was achieved by 6 months in most trials. Studies exclusively enrolling participants with cardiovascular risk factors demonstrated slightly smaller amounts of weight loss with orlistat therapy compared to those enrolling lower risk populations. Previous studies have suggested that weight loss is more difficult to achieve in patients with diabetes, possibly because of the underlying disease state or because medications used to treat diabetes tend to cause weight gain. 48 This is unfortunate because such patients may derive the most benefit from weight loss therapy. Weighted mean difference for data that are quantitatively combined and raw mean difference for data that are not. A random effects model was used for quantitative meta-analysis.
b Data not combined due to substantial statistical heterogeneity. Long-term pharmacotherapy for overweight and obesity R Padwal et al Gastrointestinal symptoms were the predominant side effect of orlistat therapy, with most studies reporting that side effects were mild and transient and decreased as patients adjusted to a low-fat diet. Whether this applies to patients in standard clinical practice, rather than a selected RCT population, is not known. Although the number of patients discontinuing therapy due to adverse effects appeared small, high study attrition rates raise the possibility that some of these events remained uncaptured. The increase in blood pressure and pulse rate observed with sibutramine therapy is of concern and further underscores the need for studies examining the effect of sibutramine therapy on mortality and cardiovascular morbidity. This agent is currently contraindicated in patients with a history of coronary artery disease, congetsive hart failure, arrhythmias, cerebrovascular disease, and uncontrolled hypertension. In the remainder of patients receiving sibutramine, careful blood pressure monitoring is mandatory.
High attrition rates in both treatment and control groups were the major methodological limitation in all studies. Authors attempted to address this by carrying forward the last observation on record to the end of the study. Such an analysis can bias results in either direction, depending on the differential drop-out rates in treatment and control arms and reasons for withdrawal. For example, patients in the placebo group may drop out of the study early because of weight gain due to lack of efficacy. Measuring their weight at the point of withdrawal will likely underestimate their weight at the end of the study period, assuming that they slowly gain weight during the rest of the follow-up period. This would underestimate the degree of weight gain in the control group and dampen the overall treatment effect. However, if nonresponders in the treatment arm drop out early leaving only responders to complete the trial, the treatment effect may be significantly overestimated. This was not observed in the four orlistat trials and one sibutramine study that did perform on-treatment analyses. Results of the completer's analyses were nearly identical to their respective LCOF analyses in these studies (data not shown). 35, 36, 38, 39, 47 Overall, it is difficult to compensate for such high attrition rates by using any form of analysis. Considerable bias may be introduced into the results of these studies, and should be remembered when interpreting the results of this review.
Several studies included in the review measured weight loss from the beginning of a 2-to 5-week run-in phase rather than at the point of randomization. As the amount of weight lost during the run-in phase of each trial was similar in both study arms, this methodological flaw had no effect on the final results of our review. 29 All studies in this review showed a positive treatment effect. This may suggest that orlistat and sibutramine produce consistent reductions in weight, but may also be explained on the basis of publication bias. We were unable to locate unpublished data during our search and may have missed such studies. To assess for possible publication bias, we generated a funnel plot of orlistat studies (Figure 4 ). This shows a paucity of points in the lower-half of the funnel, indicating that the impact of both positive and negative small studies may have been underestimated. 49, 50 Negative studies are more likely to have remained unpublished and, therefore, undetected. Interpretation and accuracy of the funnel plot is limited by the small number of total studies included in this review and the fact that publication bias may not be the only explanation for the observed pattern. 50 If one assumes that the observed results are valid, is this mild degree of weight loss of benefit? Current evidence suggests that it may be, particularly in high-risk subgroups, but more definitive data are needed. Weight reduction of approximately 5-10% of initial body weight is associated with improvements in blood pressure, lipid and glucose parameters but RCT data examining the impact of weight reduction on cardiovascular events and mortality are lacking. Recently, placebo or usual care-controlled randomized trials involving treatments such as intensive lifestyle modification (diet plus exercise), acarbose, metformin, and troglitazone have proven successful in reducing the incidence of diabetes in patients with impaired glucose tolerance, the majority of whom were overweight or obese. [51] [52] [53] [54] In follow-up periods ranging from 2.5 to 3.3 y, the incidence of type II diabetes was reduced by 25-58%, depending on the intervention studied. Intensive lifestyle modification caused the largest reduction in risk of 58% in two studies. 53, 54 Net weight loss between intervention and control arms for all trials was modest, ranging from 0.8 to 5.6 kg greater in the intervention arm of each study. These data suggest that small amounts of weight loss in this high-risk population are associated with a significant reduction in the incidence of diabetes. Whether this benefit is sustained over longer follow-up periods remains to be seen. It should also be noted that the observed results can only be attributed to the entire randomized intervention (diet/exercise7drug therapy), rather than just the observed reduction in weight. A similar trial has recently been performed comparing the effect of orlistat plus lifestyle intervention to lifestyle intervention alone in the delay/prevention of diabetes. The XENDOS trial (Xenical in the Prevention of Diabetes in Figure 4 Funnel plot of Orlistat trials.
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Obese Subjects) enrolled 3304 obese patients from Sweden, 21% of whom had impaired glucose tolerance. 55 Preliminary results showed a 37% lower incidence of diabetes in the orlistat treatment arm over a 4-y follow-up period, with a weight difference between groups of 3.9 kg at 1 y and 2.8 kg at 4 y. However, interpretation of these results is limited because attrition rates were high, reaching 52% in the orlistat group and 34% in the placebo group at 4 y. When this trial has been published in full, it will be eligible for inclusion into an updated version of this review.
Conclusions
Currently, there is a paucity of experience with most approved antiobesity agents in RCTs with follow-up periods of 1 y or greater. Sibutramine and orlistat are the most extensively studied agents, but interpretation of the data is limited because of high attrition rates. Both medications appear to have modest efficacy in promoting and maintaining weight loss. Even a modest amount of weight loss may be beneficial, particularly in high-risk individuals such as those with impaired glucose tolerance. However, longer and more methodologically rigorous studies powered to examine end points such as mortality and cardiovascular morbidity are needed before more definitive recommendations can be made regarding the role of these medications in the management of obese patients.
In the meantime, efforts should focus on the prevention of obesity in those persons who are not obese, and nonpharmacological management should remain the cornerstone of therapy in those with existing disease. Drug therapy should be considered on an individual basis, with stronger consideration given to those individuals with greater degrees of obesity and comorbid illness. Research efforts should focus on the identification and testing of more effective and better tolerated antiobesity therapies. If the growing global obesity epidemic is to be successfully curtailed, a concerted effort on all fronts will be required.
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